Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Boehringer Ingelheim
Merck
McKesson
Baxter

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR TRABECTEDIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Trabectedin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002904 ↗ Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 1 1996-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating adults with advanced solid tumors.
NCT00003939 ↗ Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 1969-12-31 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have advanced soft tissue sarcoma.
NCT00005625 ↗ Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma Completed National Cancer Institute (NCI) Phase 2 1999-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
NCT00005625 ↗ Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma Completed Memorial Sloan Kettering Cancer Center Phase 2 1999-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
NCT00017030 ↗ Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma Completed National Cancer Institute (NCI) Phase 2 2001-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma.
NCT00017030 ↗ Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma Completed Memorial Sloan Kettering Cancer Center Phase 2 2001-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma.
NCT00027508 ↗ Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma Terminated National Cancer Institute (NCI) Phase 2 2001-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trabectedin

Condition Name

Condition Name for Trabectedin
Intervention Trials
Sarcoma 13
Soft Tissue Sarcoma 11
Leiomyosarcoma 8
Ovarian Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trabectedin
Intervention Trials
Sarcoma 40
Leiomyosarcoma 15
Ovarian Neoplasms 15
Liposarcoma 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trabectedin

Trials by Country

Trials by Country for Trabectedin
Location Trials
United States 259
Italy 143
Spain 37
Germany 30
France 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trabectedin
Location Trials
California 16
New York 14
Pennsylvania 14
Massachusetts 14
Washington 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trabectedin

Clinical Trial Phase

Clinical Trial Phase for Trabectedin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 69
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trabectedin
Clinical Trial Phase Trials
Completed 50
Recruiting 16
Active, not recruiting 9
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trabectedin

Sponsor Name

Sponsor Name for Trabectedin
Sponsor Trials
PharmaMar 35
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 12
National Cancer Institute (NCI) 11
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trabectedin
Sponsor Trials
Other 94
Industry 76
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
AstraZeneca
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.